Compare
ARS Pharmaceuticals, Inc. vs Nurix Therapeutics, Inc. vs Standard Biotools Inc. vs Arcturus Therapeutics Holdings Inc.
| Latest fiscal year | ARS Pharmaceuticals, Inc. SPRY | Nurix Therapeutics, Inc. NRIX | Standard Biotools Inc. LAB | Arcturus Therapeutics Holdings Inc. ARCT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-11-30 | 2025-12-31 | 2025-12-31 |
| Revenue | $84.28M | $83.98M | $85.33M | $82.03M |
| Revenue growth (YoY) | -5.5% | +54.0% | -6.2% | -46.1% |
| Gross margin | n/a | n/a | 49.9% | n/a |
| Operating margin | -212.9% | -340.2% | -129.2% | -93.0% |
| Net margin | -203.3% | -314.9% | -87.8% | -80.2% |
| Net income | -$171.30M | -$264.46M | -$74.90M | -$65.78M |
| EPS (Diluted) | -$1.74 | -$3.05 | -$0.20 | -$2.40 |
| Operating cash flow | -$170.87M | -$249.47M | -$74.34M | -$74.27M |
| Free cash flow | -$171.21M | -$263.47M | -$82.65M | -$74.50M |
| Cash & equivalents | $41.32M | $246.96M | $120.86M | $230.91M |
| Total assets | $327.65M | $688.13M | $567.75M | $271.15M |
| Total liabilities | $213.39M | $149.39M | $143.46M | $57.16M |
| Shareholders' equity | $114.26M | $538.75M | $424.29M | $213.99M |
| Return on year-end equity | -149.9% | -49.1% | -17.7% | -30.7% |
| Shares outstanding | 99.29M | 101.81M | 386.38M | 28.41M |
Revenue, most recent five fiscal years
| Fiscal year | ARS Pharmaceuticals, Inc. | Nurix Therapeutics, Inc. | Standard Biotools Inc. | Arcturus Therapeutics Holdings Inc. |
|---|---|---|---|---|
| Latest | $84.28M Ended 2025-12-31 | $83.98M Ended 2025-11-30 | $85.33M Ended 2025-12-31 | $82.03M Ended 2025-12-31 |
| 1 year earlier | $89.15M Ended 2024-12-31 | $54.55M Ended 2024-11-30 | $91.01M Ended 2024-12-31 | $152.31M Ended 2024-12-31 |
| 2 years earlier | $30.0K Ended 2023-12-31 | $76.99M Ended 2023-11-30 | $106.34M Ended 2023-12-31 | $166.80M Ended 2023-12-31 |
| 3 years earlier | $1.32M Ended 2022-12-31 | $38.63M Ended 2022-11-30 | $97.95M Ended 2022-12-31 | $206.00M Ended 2022-12-31 |
| 4 years earlier | $5.51M Ended 2021-12-31 | $29.75M Ended 2021-11-30 | $130.58M Ended 2021-12-31 | $12.36M Ended 2021-12-31 |